National Survey on Gastroesophageal Reflux Disease (GERD) Patients
Evaluation of the Impact of Abdominal Fat on GERD Severity and GERD Frequency in General Practice
Sponsor: AstraZeneca
This observational or N/A phase trial investigates GERD and is currently completed. AstraZeneca leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
ARC ET Senans RC ET Senans, France , Ablon-sur-Seine, France , Achenheim, France , Afa, France , Agde, France , Agen, France , Agneaux, France , Aigre, France , Aigrefeuille SUR MAI, France , Aire-sur-la-Lys, France and 1614 more locations